Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.
Pooled Cohort Equation Bests Life's Essential 8, Simple 7 for Predicting Long-Term CVD Risk
Health Consequences of Climate Change with Janelle Bludorn, PA-C, MS
Cardiovascular Disease Rate is Greater in Younger Than Older Adults with OSA
Diabetes Dialogue: CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD
Mediterranean Diet Linked to Improved Markers of Cardiometabolic Health in Children, Adolescents
Anxiety, Depression Interfere with Preventive Actions to Reduce CVD Risk Factors